Rational Design, Synthesis, and Pharmacological Properties of New 1,8-Naphthyridin-2(1H)-on-3-Carboxamide Derivatives as Highly Selective Cannabinoid-2 Receptor Agonists

Citations Over TimeTop 25% of 2009 papers

Abstract

The CB(2) receptor activation can be exploited for the treatment of diseases such as chronic pain and tumors of immune origin, devoid of psychotropic activity. On the basis of our already reported 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives, new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives were designed, synthesized, and tested for their affinities toward the human CB(1) and CB(2) cannabinoid receptors. Some of the reported compounds showed a subnanomolar CB(2) affinity with a CB(1)/CB(2) selectivity ratio greater than 200 (compounds 6, 12, cis-12, 13, and cis-13). Further studies revealed that compound 12, which presented benzyl and carboxy-4-methylcyclohexylamide substituents bound in the 1 and 3 positions, exerted a CB(2)-mediated inhibitory action on immunological human basophil activation. On the human T cell leukemia line Jurkat the same derivative induced a concentration-dependent decrease of cell viability. The obtained results suggest that 1,8-naphthyridin-2(1H)-on-3-carboxamides represent a new scaffold very suitable for the development of new promising CB(2) agonists.

Related Papers

• → Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor(2000)541 cited
• → Targeting cannabinoid agonists for inflammatory and neuropathic pain(2007)101 cited
• → Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors(2004)99 cited
• → Cannabinoid CB1 and CB2 Receptor Ligand Specificity and the Development of CB2-Selective Agonists(2008)88 cited
• → Identification and biochemical analyses of selective CB2 agonists(2019)10 cited